Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3058% below fair value
$1.52−0.11 (-6.75%)
Close on Nov 17, 2026Market cap $93.66MP/E –Yield –
Voyager Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Voyager Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$117.19M. For fiscal 2025 it was -$131.84M. The highest annual figure on record is $122.01M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$131.84M | – |
| FY2024 | Dec 31, 2024 | -$83.29M | -168.3% |
| FY2023 | Dec 31, 2023 | $122.01M | – |
| FY2022 | Dec 31, 2022 | -$50.84M | – |
| FY2021 | Dec 31, 2021 | -$73.62M | -368.8% |
| FY2020 | Dec 31, 2020 | $27.38M | – |
| FY2019 | Dec 31, 2019 | -$51.68M | – |
| FY2018 | Dec 31, 2018 | -$91.10M | – |
| FY2017 | Dec 31, 2017 | -$71.86M | – |
| FY2016 | Dec 31, 2016 | -$41.30M | – |
| FY2015 | Dec 31, 2015 | -$20.25M | – |
| FY2014 | Dec 31, 2014 | -$14.37M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$26.39M | – |
| Q1 FY2026 | Mar 31, 2026 | -$30.27M | – |
| Q4 FY2025 | Dec 31, 2025 | -$29.93M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.59M | – |
| Q2 FY2025 | Jun 30, 2025 | -$36.63M | – |
| Q1 FY2025 | Mar 31, 2025 | -$34.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$38.30M | -170.8% |
| Q3 FY2024 | Sep 30, 2024 | -$13.78M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.03M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.18M | -113.2% |
| Q4 FY2023 | Dec 31, 2023 | $54.06M | – |
| Q3 FY2023 | Sep 30, 2023 | -$29.51M | -304.3% |
| Q2 FY2023 | Jun 30, 2023 | -$25.43M | – |
| Q1 FY2023 | Mar 31, 2023 | $122.88M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.56M | -530.8% |
| Q3 FY2022 | Sep 30, 2022 | $14.44M | – |
| Q2 FY2022 | Jun 30, 2022 | -$19.37M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.35M | – |
| Q4 FY2021 | Dec 31, 2021 | $5.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$25.15M | -129.7% |
| Q2 FY2021 | Jun 30, 2021 | -$28.59M | – |
| Q1 FY2021 | Mar 31, 2021 | -$25.59M | – |
| Q4 FY2020 | Dec 31, 2020 | -$23.73M | – |
| Q3 FY2020 | Sep 30, 2020 | $84.53M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.98M | -197.7% |
| Q1 FY2020 | Mar 31, 2020 | -$24.43M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.81M | – |
| Q2 FY2019 | Jun 30, 2019 | $9.19M | – |
| Q1 FY2019 | Mar 31, 2019 | -$29.29M | – |
| Q4 FY2018 | Dec 31, 2018 | -$23.16M | – |
| Q3 FY2018 | Sep 30, 2018 | -$21.15M | – |
| Q2 FY2018 | Jun 30, 2018 | -$25.69M | – |
| Q1 FY2018 | Mar 31, 2018 | -$21.09M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.35M | – |
| Q3 FY2017 | Sep 30, 2017 | -$23.36M | – |
| Q2 FY2017 | Jun 30, 2017 | -$18.64M | – |
| Q1 FY2017 | Mar 31, 2017 | -$17.52M | – |
| Q4 FY2016 | Dec 31, 2016 | -$13.84M | – |
| Q3 FY2016 | Sep 30, 2016 | -$10.37M | – |
See a number that looks wrong?